Hepatitis treatment

Hepatitis and hepatic fibrosis prevent liver cancer alternative : Gycyrrhizin
1 . Promote liver function (GPT, GOT, TB) returned to normal, liver histology (Histology) improved.(2) reduce liver cancer incidence rate 50 ~ 60% (Cancer 1997, Oncology 2002 ─ 15 years of long-term studies ) .3 patients with interferon invalid , you can still reduce the rate of liver cancer 49% (Dig. Dis. And Sci. 2006).

Efficacy against Hepatitis B :
Within four weeks of liver function improvement rate chart
Significantly reduce the inflammation of the liver index , the effective rate of 78% or more:109 chronic hepatitis B patients , the use of four weeks , a significant improvement in liver function .ALT levels ─ the effect of 51% , effective 78%.AST levels ─ the efficiency 59% , effective 83%.TB value ─ the effect of 36% , effective 64%.( Reference : Hepatology research 2000.)



Within eight weeks of liver function improvement rate chart
194 chronic hepatitis B patients , the use of eight weeks with different doses (100mL, 40mL).ALT values ​​<1 .5x="" .="" 74="" 79="" br="" uln="" were="">ALT levels <40 .="" 57="" 58="" br="" iu="" l="" were="">─ improved symptoms of hepatitisJaundice disappeared, spirit, appetite , sleep quality improved.Eliminate fatigue , bloating disappear.─ safe, no side effects, long-term use90% of patients had no adverse effects occurThe effect ─ ALT, AST, TB (Total bilirubin) <1 .5="" br="" disappears.="" jaundice="" normal="" times="">Effective ─ including the aforementioned lower values ​​less than 50% improvement in symptoms in patients .( Reference : Hepatology research 2000, 2002.)






Efficacy against Hepatitis C :
Reduced rate of liver cancer fifteen years
─ cirrhosis, liver cancer incidence by 50 to 60%403 CHC patients , the use of Glycyrrhizin up to 15 years , proven to reduce cirrhosis (Cirrhosis) and the incidence of hepatocellular carcinoma (HCC).F1 reduced the incidence of liver cancer patients 50% (6% vs. 12%, n = 193, p = 0.040).F2 reduced the incidence of liver cancer patients 53% (15% vs. 32%, n = 128, p = 0.005).F3 decreased incidence of liver cancer patients 21% (40% vs. 51%, n = 74, p = 0.071).High-risk group ( > 50 years old , F3) if the ALT value control less than 75 IU / L, which reduced the incidence of hepatocellular carcinoma 66% (n = 31, p = 0.057).( Reference : Oncology 2002.)


Reduced rate of liver cancer fifteen years
─ also effective than interferon ?Analysis of chronic hepatitis C , interferon treatment group of 1191 , the use of Glycyrrhizin treatment group were 453 .Interferon (IFN) treatment group compared with the control group, the incidence of liver cancer decreased 33% (n = 1191, p = 0.14).Glycyrrhizin treatment group, the incidence of liver cancer compared with the control group decreased 60% (n = 453, p = 0.044, Multivariate analysis using time ≧ 10 years , 1970 ~ 1984 Kenji Ikeda, MD)( Reference : APASL 2002.)




Main Ingredients:Each mL of Glycyrrhizinate monoammonium 2.04mg ( equivalent Glycyrrhizin 2.0mg), each ampoule 20mL.

Dose:Intravenous injection , once a day , every 2 to 3 ampoules , continuous injection of 2 to 4 weeks. If ALT unable fell 60 IU / L or less, increase to once a day , every five ampoules , for 2 to 4 weeks , the maximum daily dose of 5 ampoules .

Maintenance dose:If ALT dropped 60 IU / L or less, 2 to 3 times per week , every 2 to 3 ampoules ; and increase or decrease the dose according to the disease .

Indications:Maintenance of normal liver function , drug allergy, food allergy ; applicable chronic B, C hepatitis patients .→ interferon (IFN) combined class nuclear drugs (NRTI, ex: Lamivudine or Ribavirin) ineffective treatment (Non-responder) or re- recurrence (Relapser).→ intolerable side effects of interferon or class of nuclear medicines for patients (Side effects)→ expected poor efficacy (CHC Genotype1, 4, 5, 6) of the patients with chronic hepatitis C→ disease considerations can not use IFN + NRTI therapy such as :
Decompensated liver disease ( if jaundice, ascites , hepatic coma ) .Autoimmune diseases such as : rheumatoid arthritis , psoriasis , autoimmune hepatitis.Immunosuppressants user .Elderly ( > 50 years ) .Depression, anxiety , insomnia.Alcoholic hepatitis .Hematopoietic function problems .Kidney disease .Anemia.Diabetes.Cardiovascular disease.Thyroid dysfunction .

Side effects:Safe, almost no side effects, however still need to pay attention to pseudo- sexual aldehyde tallow alcohol hyperparathyroidism (Pseudo-aldosteronism) resulting from sodium retention , hypokalemia , hypertension , clinical manifestations of lower extremity edema, poor muscle strength , muscle pain, headaches, other side effects such as : tiredness , abnormal sensation , skin rash.